Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Wuhan General Group Inc (EM) WUHN

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Wuhan General Group (China), Inc., a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Reno, Nevada.


EXPM:WUHN - Post by User

Wuhan General Group Inc (EM)
<< Previous
 Bullboard Posts
User Avatar Image
(10)
•••
  • joe9904X
Post by joe9904on Feb 02, 2021 3:59pm
267 Views
Post# 32449640

F19 and F20 Executive summary

F19 and F20 Executive summary

Fiscal Year 2020 Highlights Versus Fiscal 2019

  • Net income for the year $409,996 US, compared to $0 US
  • Increase in current assets to $596,549 US from $83,817 US
  • Decrease in liabilities to $89,689 US from $659,145 US
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities